デフォルト表紙
市場調査レポート
商品コード
1533933

ホジキンスリンパ腫治療の世界市場

Hodgkins Lymphoma Treatment

出版日
ページ情報
英文 127 Pages
納期
即日から翌営業日
適宜更新あり
ホジキンスリンパ腫治療の世界市場
出版日: 2024年08月14日
発行: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
ページ情報: 英文 127 Pages
納期: 即日から翌営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

ホジキンスリンパ腫治療の世界市場は2030年までに19億米ドルに達する見込み

2023年に11億米ドルと推定されたホジキンスリンパ腫治療の世界市場は、分析期間2023-2030年にCAGR 8.8%で成長し、2030年には19億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである放射線療法は、CAGR 9.9％を記録し、分析期間終了までに10億米ドルに達すると予測されます。化学療法分野の成長率は、分析期間を通じてCAGR 6.8％と推定されます。

米国市場は2億8,050万米ドルと推定、中国はCAGR 8.4％で成長予測

米国のホジキンスリンパ腫治療市場は、2023年に2億8,050万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 8.4%で推移し、2030年には3億380万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ8.2%と7.3%と予測されています。欧州では、ドイツがCAGR約6.9%で成長すると予測されています。

主要動向と促進要因

リンパ系がんの一種であるホジキンリンパ腫は、リード・スタンバーグ細胞の存在を特徴とし、一般的にリンパ節の腫脹、発熱、寝汗、体重減少などの症状を呈します。ホジキンリンパ腫の治療は著しく進歩し、特に早期に診断された場合の治癒率は高いです。標準的な治療レジメンには化学療法と放射線療法の併用が含まれ、大多数の症例で寛解を達成するのに非常に有効です。さらに最近では、CD30指向性モノクローナル抗体であるブレンツキシマブ・ベドチンのような分子標的治療薬のイントロダクションが、再発した患者や初期治療に反応しなかった患者に代替療法を提供しています。これらの進歩は患者の予後を著しく改善し、従来の治療に伴う長期合併症を減少させています。

研究が進むにつれて、治療に関連する副作用を最小限に抑え、高い治癒率を維持しながら長期的な毒性のリスクを低減するために治療レジメンを調整することが重視されるようになっています。これには、治療範囲や治療期間を決定するためのPET検査も含まれ、化学療法や放射線療法を長期間受けることによるリスクを回避できる患者もいます。臨床試験では、治療成績を向上させ、再発の可能性を減少させるために、標準的な治療法に新しい薬剤を併用することの有効性が引き続き検討されています。例えば、免疫系ががん細胞を認識して破壊するのを助けるチェックポイント阻害剤がホジキンリンパ腫で試験され、有望な結果が得られています。

ホジキンリンパ腫治療市場の成長は、病気の早期発見と正確な発見を可能にし、患者の転帰を改善する診断技術の進歩など、いくつかの要因によってもたらされます。特に免疫療法や標的治療の領域における新しい治療法の研究開発への投資の増加は、治療状況を急速に変化させています。さらに、患者意識とアドボカシーの高まりにより、より多くの患者が適時に適切な治療を受けられるようになっています。がん検診と教育に重点を置いた世界の保健活動も、発見率と治療率の向上に寄与しています。有望な新治療の早期実用化に向けた規制当局の支援は、患者への提供を加速させ、市場の成長をさらに刺激します。

調査対象企業の例（注目の37社）

  • Actiza Pharmaceutical Pvt., Ltd.
  • Alkem Laboratories Limited
  • Biogen, Inc.
  • Bristol-Myers Squibb Company
  • Cipla Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi USA
  • Incyte Corporation
  • Leadiant Biosciences, Inc.
  • LGM Pharma
  • Merck & Co., Inc.
  • Novartis International AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP26830

Global Hodgkins Lymphoma Treatment Market to Reach US$1.9 Billion by 2030

The global market for Hodgkins Lymphoma Treatment estimated at US$1.1 Billion in the year 2023, is expected to reach US$1.9 Billion by 2030, growing at a CAGR of 8.8% over the analysis period 2023-2030. Radiotherapy, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$1.0 Billion by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$280.5 Million While China is Forecast to Grow at 8.4% CAGR

The Hodgkins Lymphoma Treatment market in the U.S. is estimated at US$280.5 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$303.8 Million by the year 2030 trailing a CAGR of 8.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.2% and 7.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.9% CAGR.

Key Trends and Drivers

Hodgkin's lymphoma, a type of lymphatic cancer, is characterized by the presence of Reed-Sternberg cells and typically presents with symptoms like swollen lymph nodes, fever, night sweats, and weight loss. Treatment for Hodgkin's lymphoma has evolved significantly, with high cure rates, especially when diagnosed early. The standard treatment regimen includes a combination of chemotherapy and radiation therapy, which has been very effective in achieving remission in a majority of cases. More recently, the introduction of targeted therapies such as the CD30-directed monoclonal antibody, brentuximab vedotin, has provided an alternative for patients who relapse or do not respond to initial treatment. These advancements have significantly improved the prognosis for patients, reducing the long-term complications associated with traditional therapies.

As research progresses, there is a growing emphasis on minimizing treatment-related side effects and tailoring therapy regimens to reduce the risk of long-term toxicity while maintaining high cure rates. This includes the use of PET scans to guide the extent and duration of treatment, allowing some patients to avoid the risks associated with prolonged exposure to chemotherapy and radiation. Clinical trials continue to explore the efficacy of combining newer agents with standard therapies to enhance outcomes and decrease the likelihood of relapse. For example, checkpoint inhibitors that help the immune system recognize and destroy cancer cells are being tested in Hodgkin's lymphoma with promising results.

The growth in the Hodgkin's lymphoma treatment market is driven by several factors, including advances in diagnostic techniques that allow for earlier and more accurate detection of the disease, improving patient outcomes. Increased investment in research and development of new therapies, particularly in the realm of immunotherapy and targeted treatments, is rapidly transforming the therapeutic landscape. Additionally, the rise in patient awareness and advocacy ensures that more patients seek and receive timely, appropriate treatment. Global health initiatives focusing on cancer screening and education also contribute to the increased detection and treatment rates. Regulatory support for fast-tracking promising new treatments accelerates their availability to patients, further stimulating market growth.

Select Competitors (Total 37 Featured) -

  • Actiza Pharmaceutical Pvt., Ltd.
  • Alkem Laboratories Limited
  • Biogen, Inc.
  • Bristol-Myers Squibb Company
  • Cipla Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi USA
  • Incyte Corporation
  • Leadiant Biosciences, Inc.
  • LGM Pharma
  • Merck & Co., Inc.
  • Novartis International AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Hodgkins Lymphoma Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advancements in Chemotherapy and Radiotherapy Techniques
    • Development of Targeted Therapies and Monoclonal Antibodies
    • Increasing Effectiveness of Personalized Treatment Plans
    • Global Incidence of Hodgkin's Lymphoma and Epidemiological Trends
    • Patient Quality of Life Considerations Driving Treatment Innovations
    • Role of Combination Therapies in Treatment Protocols
    • Advances in Diagnostic Technologies Enhancing Early Detection
    • Healthcare Infrastructure Improvements and Their Impact on Availability
    • The Economic Impact of Lifelong Treatment and Monitoring
    • Advocacy and Support Groups Influencing Policy Changes
    • Challenges in Managing Long-Term Survivorship and Side Effects
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Hodgkins Lymphoma Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Hodgkins Lymphoma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Hodgkins Lymphoma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Hodgkins Lymphoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Radiotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Radiotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Radiotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hodgkins Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Hodgkins Lymphoma Treatment by Therapy - Percentage Breakdown of Value Sales for Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Canada Historic Review for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: Canada 16-Year Perspective for Hodgkins Lymphoma Treatment by Therapy - Percentage Breakdown of Value Sales for Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • JAPAN
    • Hodgkins Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 23: Japan Recent Past, Current & Future Analysis for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Japan Historic Review for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: Japan 16-Year Perspective for Hodgkins Lymphoma Treatment by Therapy - Percentage Breakdown of Value Sales for Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • CHINA
    • Hodgkins Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: China Historic Review for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: China 16-Year Perspective for Hodgkins Lymphoma Treatment by Therapy - Percentage Breakdown of Value Sales for Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • EUROPE
    • Hodgkins Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Hodgkins Lymphoma Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Hodgkins Lymphoma Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Hodgkins Lymphoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Hodgkins Lymphoma Treatment by Therapy - Percentage Breakdown of Value Sales for Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • FRANCE
    • Hodgkins Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 35: France Recent Past, Current & Future Analysis for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: France Historic Review for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: France 16-Year Perspective for Hodgkins Lymphoma Treatment by Therapy - Percentage Breakdown of Value Sales for Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • GERMANY
    • Hodgkins Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 38: Germany Recent Past, Current & Future Analysis for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Germany Historic Review for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Germany 16-Year Perspective for Hodgkins Lymphoma Treatment by Therapy - Percentage Breakdown of Value Sales for Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 41: Italy Recent Past, Current & Future Analysis for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Italy Historic Review for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Italy 16-Year Perspective for Hodgkins Lymphoma Treatment by Therapy - Percentage Breakdown of Value Sales for Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Hodgkins Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 44: UK Recent Past, Current & Future Analysis for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: UK Historic Review for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: UK 16-Year Perspective for Hodgkins Lymphoma Treatment by Therapy - Percentage Breakdown of Value Sales for Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Hodgkins Lymphoma Treatment by Therapy - Percentage Breakdown of Value Sales for Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Hodgkins Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Hodgkins Lymphoma Treatment by Therapy - Percentage Breakdown of Value Sales for Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 53: Rest of World Recent Past, Current & Future Analysis for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Rest of World Historic Review for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Rest of World 16-Year Perspective for Hodgkins Lymphoma Treatment by Therapy - Percentage Breakdown of Value Sales for Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030

IV. COMPETITION